Pursuant to the terms of the merger agreement, upon completion, Bigfoot became a wholly-owned subsidiary of Abbott. The companies declined to disclose financial terms.
Abbott announced on Sept. 5 that it entered into a definitive agreement to acquire the smart insulin management company. Their longstanding relationship dates back to 2017, with the medtech giant even leading a financing round for Bigfoot in 2020.
Get the full story at our sister site, Drug Delivery Business News.
Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here’s what you need to know for today, September 22, 2023.
Fast Five by MassDevice · Hologic, Bayer partnering for mammography imaging, Medtronic wins CE mark for next-gen CGMThere are more funding raises in the news this week. The first one is from MedTrace, which raised $19 million for its PET-boosting technology. Fast Five hosts Sean Whooley and Danielle Kirsh go over what the funding will go toward and the technology they’re developing. Read more here>>
ProSomnus is raising $10 million for its CPAP alternative. Find out what the technology is and how optimistic executives are about the future of the technology. Read more here>>
Whooley details a regulatory nod for Quantum Surgical’s surgical robot in China. Hear about what the robot does, what kind of treatment it offers and …
Further progress for Relievant and Intracept follows Tuesday’s major news of an agreement for Boston Scientific to acquire the company. Boston Scientific officials went into further detail on their expectations for the Relievant deal at the company’s Investor Day yesterday.
Minneapolis-based Relievant develops the Intracept intraosseous nerve ablation system for chronic pain. The minimally invasive, FDA-cleared, same-day, outpatient procedure treats chronic vertebrogenic low back pain. Intracept utilizes targeted radiofrequency energy to ablate the basivertebral nerve (BVN). This stops the nerve from transmitting pain signals to the brain. The procedure takes approximately one hour to perform.
Relievant based its simulator system for Intracept on Medabilit…
Hologic (Nasdaq: HOLX) + and Bayer today announced an international partnership focused on improving breast cancer detection.
The companies teamed up to deliver contrast-enhanced mammography (CEM) solutions across Europe, Canada and Asia Pacific. CEM, a highly sensitive, relatively low-cost breast imaging modality combines digital mammography with contrast agent administration. It supports breast cancer diagnosis and guides treatment decisions.
Marlborough, Massachusetts-based Hologic said the partnership brings together its mammography gantries with Bayer’s CEM-approved injection systems. It enables the administration of contrast media during a mammography examination, according to a news release. The agreement allows the companies to support radiologists with a comprehensive product package and hands-on training.
“Over the past several years, we’ve seen an increased interest in contrast-enhanced mammogra…
LivaNova (Nasdaq: LIVN) + announced today that Marco Dolci intends to retire from his position as president of the cardiopulmonary business unit.
Dolci plans to retire by Dec. 31, 2023, continuing in his role to support the transition of responsibilities through the end of the year. The company appointed Franco Poletti to serve as interim GM of cardiopulmonary to support the transition. He’ll do so in addition to his current role as VP of cardiopulmonary for Europe, effective immediately.
The London-based medtech company plans to retain a leading international executive search firm to help find a permanent successor. It’s another high-profile executive departure for the company, which saw CEO Damien McDonald resign in April.
LivaNova noted Dolci’s role in the progress of its Essenz perfusion system, which just last month hit another regulatory milestone.
“On behalf of the board, the exec…
15 O-water has a reputation as a gold-standard radioactive tracer for PET imaging, but supply chain problems around the substance have hindered adoption. Hørsholm, Denmark–based MedTrace, which opened a U.S. headquarters in downtown Minneapolis last year, seeks to solve the problem by moving 15 O-water production inside hospitals with an automated point-of-care chemistry system. A Phase 3 clinical trial of the system kicked off last year.
The investments surpassed MedTrace Pharma’s goal of raising €15 million — an achievement in a challenging fundraising environment that shows investors are confident i…
News of the regulatory nod comes just weeks after the last one for Quantum. It announced CE mark expansion for Epione to treat lung tumors earlier this month.
Montpellier, France-based Quantum’s flagship Epione robot enables the early and minimally invasive treatment of abdominal tumors. It allows surgeons to treat inoperable tumors that are particularly hard to reach due to size or location. The simple, effective platform provides treatment at an early stage.
A robotic-assisted percutaneous ablation system, Epione uses a robotic arm, a navigation system and a camera. It inserts a needle through the skin to the tumor and destroys it.
Epione can treat tumors in the liver, kidney and pancreas, in addition to the lung expansion it just received. It…
The company earmarked the new capital to optimize its core business operations and support its strategic growth initiatives. It aims to achieve cash flow breakeven with these efforts. Spring Mountain Capital and Cetus Capital led the financing. The company’s Executive Chair, CEO and CFO also participated.
Pleasanton, California-based ProSomnus develops an alternative to CPAPs for treating obstructive sleep apnea (OSA). Its intraoral medical devices precisely track the treatment plan and anatomy of each patient. The FDA-cleared, non-invasive mouthguard-like devices have the backing of a “growing body of clinical investigations,” ProSomnus says.
It may be an opportune time for companies developing alternatives to to CPAP machines as Philips continues working to resolve it…
The all-in-one, disposable CGM features a simple, two-step insertion process for people with diabetes using multiple daily injections (MDI). Medtronic’s newest no-fingerstick sensor eliminates the need for overtape, too. It seamlessly integrates with the InPen smart insulin pen for real-time, personalized dosing guidance to simplify diabetes management.
Medtronic plans to begin a phased launch for Simplera at the European Association for the Study of Diabetes (EASD) 59th Annual Meeting. It takes place in Hamburg, Germany, from Oct. 2-6.
Commercializing a new CGM comes at a good time for Medtronic, which could see the benefits from the newly popular GLP-1 drug class. Analysts recently outlined the ways in which those drugs m…
Welcome to the MassDevice Fast Five medtech news podcast, the show that keeps you up-to-date on the latest breakthroughs in medical technology. Here’s what you need to know for today, September 21, 2023.
Fast Five by MassDevice · Boston Scientific targets M&A to reach ‘next level’, EU sees potential antitrust activity in medtechToday’s news covers Orthofix’s launch of its new fixation system and the first cases with the device were performed. Fast Five hosts Sean Whooley and Danielle Kirsh discuss what the system offers to patients and surgeons. Read more here>>
There is also more brain-computer interface (BCI) news this week from Neuralink, which has opened recruitment for its first-in-human BCI trial. Hear more about the study’s details and the path Neuralink took to get to this point. Read more here>>
Surgical robots are dominating the news this week. This time, CMR Surgical brought in $165 million in a fundi…
Download this white paper to discover how real world evidence connects data and insights across the total product life cycle to support IVD clinical performance and formulate value narratives for optimizing IVD market access.
Download the white paper from Iqvia Medtech to learn more.
var gform;gform||(document.addEventListener("gform_main_scripts_loaded",function(){gform.scriptsLoaded=!0}),window.addEventListener("DOMContentLoaded",function(){gform.domLoaded=!0}),gform={domLoaded:!1,scriptsLoaded:!1,initializeOnLoaded:function(o){gform.domLoaded&&gform.scriptsLoaded?o():!gform.domLoaded&&gform.scriptsLoaded?window.addEventListener("DOMContentLoaded",o):document.addEventListener("gform_main_scripts_loaded",o)},hooks:{action:{},filter:{}},addAction:function(o,n,r,t){gform.addHook("action",o,n,r,t)},addFilter:function(o,n,r,t){gform.addHook("filter",o,n,r,t)},doAction:function(o){gform.doHook("action",o,arguments)},applyFilters:function(o){return gform.doHook("fi…
The registry evaluates the Acurate Prime aortic valve system, the Marlborough, Massachusetts-based company’s next-generation technology. It enhances the Acurate neo2 transcatheter aortic valve replacement (TAVR) system, including a full-sized matrix. The system treats patients with severe symptomatic aortic stenosis across all surgical risk levels.
Boston Scientific’s study investigates the safety and effectiveness of the larger Acurate Prime aortic valve XL (29mm). It includes 50 nonrandomized patients across 20 centers in the U.S., according to a LinkedIn post. All subjects previously enrolled in the main randomized controlled trial cohort of the ACURATE IDE trial.
In the non-randomized registry, a cohort of subjects receive Acurate Prime. Boston Scie…